I agree! We will rip here soon.
I did not expect us to trade under .05 but people are crazy if they don't load up here!
"Viaderma just announced that it has placed the first order from their product manufacturer for Viabecline 'ahead of a rollout wider scale rollout', and also gave us some indication of what numbers it expects to hit this year on its sales from the product. During 2017, sales are expected to total somewhere in the region of 500,000 units, and the rollout should kick off in California over the next few weeks. This rollout is being carried out through online, through an online network of affiliates, and the products are anticipated to sell for approximately $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers. Exactly what this wholesale price will be remains to be seen, but its reasonable to assume that the centers will pick up a between 50-60% discount on the bottle price."
If you calculate the 500,000 units with a 60% discount (wholesale), I'm assuming wholesale will make up only part of the sales, however..
500,000 x .40 = $25,000,000
$25,000,000/$3,800,000 (current market cap) = 6.58
Current share price, .019 x 6.58 = .125
Based on 1x's annual revenues, and I don't know of any company trading at 1x's annual revenues.
That's why we are incredibly undervalued. Sales are based on one product line, not to mention 5+ patent pending applications (from previous PR's), plus future sales contracts.
Look at OW(P, its trading at $2.73, market cap $370 mill, two patents, 6 pending and no sales.
$VDRM
News 
Market Data 
Discover 
AI
